Laboratory Monitoring for JAK Inhibitors and Key Takeaways

EP: 1.Alopecia Areata Clinical Presentation and Challenges in Treatment

EP: 2.Defining Alopecia Areata Severity and Navigating Treatment Options

EP: 3.Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata

EP: 4.Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers

EP: 5.Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata

Now Viewing

EP: 6.Laboratory Monitoring for JAK Inhibitors and Key Takeaways

Video content above is prompted by the following:

• Given this patient’s clinical picture, what initial dosing would you recommend?
• What monitoring should be done before and during treatment with baricitinib? How does this differ from monitoring with ritlecitinib?
• What can this patient expect in terms of efficacy and safety with baricitinib?
• When would topical immunotherapy be considered for patients with severe alopecia areata? How do you decide between topical immunotherapy and JAK inhibitors for your patients?
• Based on our discussion today, what key insights or new perspectives could you share regarding treatment considerations for severe alopecia areata?
• What treatment gaps remain in alopecia areata management?
• What take-home messages or practice pearls do you have for clinicians treating patients with alopecia areata?